Legislation & Regulation

On March 1, 2019, AMCP provided comments to CMS in response to its 2020 for Medicare Part D Call Letter. AMCP offered comments on the following sections of the notice; Part D Benefit Parameters for Non-Defined Standard Plans; Formulary Submissions; Medication Therapy Management (MTM); and Part D Mail Order Auto-Ship Modifications.

Press Release: According to a newly released survey from AMCP, nearly 63 percent of Medicare beneficiaries say they would recommend MTM services provided under the Part D prescription drug program to friends and relatives.

Opioid Legislation Passed by the U.S. House of Representatives in June 2018.

AMCP's legislative & regulatory position statements on a wide range of issues impacting managed care pharmacy. AMCP's position statements are regularly reviewed and updated by the AMCP Board of Directors.

AMCP webinar that reviewed the provisions contained in the draft 2020 CMS Medicare Part D Call Letter that was released by the Centers for Medicare and Medicaid Services (CMS) on January 30, 2019.

Read about the widespread support for this important legislation that will increase competition and decrease patients' drug costs.

Press Release: AMCP CEO Susan A. Cantrell, RPh, CAE, issued the following statement on HHS’s proposed rule to eliminate negotiated rebates for pharmaceuticals under Medicare Part D and managed Medicaid programs.